Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Active not recruiting 7Not yet recruiting 3Recruiting 2Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 1

Conditions

Triple Negative Breast Neoplasms 1Adenoma, Islet Cell 1

Interventions

Specimen Handling 311Magnetic Resonance Spectroscopy 266pembrolizumab 251Carboplatin 184Cyclophosphamide 176Biopsy 172Cisplatin 157Gemcitabine 134Paclitaxel 131Bevacizumab 124fludarabine 117Radiotherapy 108Nivolumab 108Oxaliplatin 88Docetaxel 87Fluorouracil 85Capecitabine 83venetoclax 82Dexamethasone 77Pemetrexed 72Rituximab 71Leucovorin 69Drug Therapy 69atezolizumab 67durvalumab 66Radiosurgery 65Blood Specimen Collection 65Standard of Care 63Doxorubicin 63Radiation 61

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Colony-Stimulating Factors × 90 days × Clear all
NCT06202066 2026-05-28

Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas

Roswell Park Cancer Institute

Phase 2 Recruiting
60 enrolled

Adenoma, Islet Cell

NCT07078604 2026-04-07

A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer

University of Washington

Phase 2 Recruiting
20 enrolled
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡